Specialty Retail
Compare Stocks
5 / 10Stock Comparison
EYE vs NVST vs HSIC vs DRVN vs AMSF
Revenue, margins, valuation, and 5-year total return — side by side.
Medical - Equipment & Services
Medical - Distribution
Auto - Dealerships
Insurance - Specialty
EYE vs NVST vs HSIC vs DRVN vs AMSF — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | |||||
|---|---|---|---|---|---|
| Industry | Specialty Retail | Medical - Equipment & Services | Medical - Distribution | Auto - Dealerships | Insurance - Specialty |
| Market Cap | $1.81B | $4.04B | $8.09B | $2.26B | $569M |
| Revenue (TTM) | $1.99B | $2.81B | $13.18B | $2.17B | $325M |
| Net Income (TTM) | $30M | $68M | $398M | $-198M | $46M |
| Gross Margin | 56.5% | 55.1% | 29.1% | 52.1% | 47.6% |
| Operating Margin | 3.0% | 9.0% | 5.8% | -7.3% | 17.8% |
| Forward P/E | 32.6x | 17.2x | 13.3x | 10.9x | 14.4x |
| Total Debt | $695M | $1.71B | $3.69B | $4.00B | $491K |
| Cash & Equiv. | $39M | $1.21B | $156M | $170M | $62M |
EYE vs NVST vs HSIC vs DRVN vs AMSF — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | Jan 21 | May 26 | Return |
|---|---|---|---|
| National Vision Hol… (EYE) | 100 | 49.2 | -50.8% |
| Envista Holdings Co… (NVST) | 100 | 68.3 | -31.7% |
| Henry Schein, Inc. (HSIC) | 100 | 107.1 | +7.1% |
| Driven Brands Holdi… (DRVN) | 100 | 48.9 | -51.1% |
| AMERISAFE, Inc. (AMSF) | 100 | 54.6 | -45.4% |
Price return only. Dividends and distributions are not included.
Quick Verdict: EYE vs NVST vs HSIC vs DRVN vs AMSF
Each card shows where this stock fits in a portfolio — not just who wins on paper.
EYE is the #2 pick in this set and the best alternative if growth exposure is your priority.
- Rev growth 9.0%, EPS growth 202.8%, 3Y rev CAGR 6.5%
- 9.0% revenue growth vs DRVN's 1.5%
- +46.3% vs AMSF's -29.2%
NVST lags the leaders in this set but could rank higher in a more targeted comparison.
HSIC ranks third and is worth considering specifically for valuation efficiency.
- PEG 4.21 vs NVST's 11.53
- Lower P/E (13.3x vs 14.4x)
DRVN is the clearest fit if your priority is income & stability and defensive.
- Dividend streak 2 yrs, beta 0.68
- Beta 0.68, current ratio 1.52x
AMSF carries the broadest edge in this set and is the clearest fit for long-term compounding and sleep-well-at-night.
- 31.8% 10Y total return vs HSIC's 5.3%
- Lower volatility, beta 0.23, Low D/E 0.2%, current ratio 0.32x
- 14.3% margin vs DRVN's -9.1%
- Beta 0.23 vs NVST's 1.65, lower leverage
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 9.0% revenue growth vs DRVN's 1.5% | |
| Value | Lower P/E (13.3x vs 14.4x) | |
| Quality / Margins | 14.3% margin vs DRVN's -9.1% | |
| Stability / Safety | Beta 0.23 vs NVST's 1.65, lower leverage | |
| Dividends | 8.4% yield; the other 4 pay no meaningful dividend | |
| Momentum (1Y) | +46.3% vs AMSF's -29.2% | |
| Efficiency (ROA) | 5.6% ROA vs DRVN's -4.2%, ROIC 21.9% vs -2.2% |
EYE vs NVST vs HSIC vs DRVN vs AMSF — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
EYE vs NVST vs HSIC vs DRVN vs AMSF — Financial Metrics
Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
HSIC leads in 1 of 6 categories
AMSF leads 1 • EYE leads 1 • NVST leads 0 • DRVN leads 0 • 3 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
Evenly matched — EYE and AMSF each lead in 2 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
HSIC is the larger business by revenue, generating $13.2B annually — 40.6x AMSF's $325M. AMSF is the more profitable business, keeping 14.3% of every revenue dollar as net income compared to DRVN's -9.1%. On growth, EYE holds the edge at +15.1% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | |||||
|---|---|---|---|---|---|
| RevenueTrailing 12 months | $2.0B | $2.8B | $13.2B | $2.2B | $325M |
| EBITDAEarnings before interest/tax | $153M | $342M | $1.1B | $17M | $58M |
| Net IncomeAfter-tax profit | $30M | $68M | $398M | -$198M | $46M |
| Free Cash FlowCash after capex | $73M | $220M | $561M | $41M | $8M |
| Gross MarginGross profit ÷ Revenue | +56.5% | +55.1% | +29.1% | +52.1% | +47.6% |
| Operating MarginEBIT ÷ Revenue | +3.0% | +9.0% | +5.8% | -7.3% | +17.8% |
| Net MarginNet income ÷ Revenue | +1.5% | +2.4% | +3.0% | -9.1% | +14.3% |
| FCF MarginFCF ÷ Revenue | +3.7% | +7.8% | +4.3% | +1.9% | +2.5% |
| Rev. Growth (YoY)Latest quarter vs prior year | +15.1% | +14.4% | +7.7% | -9.5% | +10.3% |
| EPS Growth (YoY)Latest quarter vs prior year | +111.3% | +130.0% | +14.9% | +5.1% | -8.5% |
Valuation Metrics
HSIC leads this category, winning 3 of 7 comparable metrics.
Valuation Metrics
At 12.3x trailing earnings, AMSF trades at a 86% valuation discount to NVST's 86.7x P/E. Adjusting for growth (PEG ratio), HSIC offers better value at 6.84x vs NVST's 58.08x — a lower PEG means you pay less per unit of expected earnings growth.
| Metric | |||||
|---|---|---|---|---|---|
| Market CapShares × price | $1.8B | $4.0B | $8.1B | $2.3B | $569M |
| Enterprise ValueMkt cap + debt − cash | $2.5B | $4.5B | $11.6B | $6.1B | $508M |
| Trailing P/EPrice ÷ TTM EPS | 61.70x | 86.73x | 21.56x | -7.55x | 12.27x |
| Forward P/EPrice ÷ next-FY EPS est. | 32.60x | 17.21x | 13.26x | 10.90x | 14.42x |
| PEG RatioP/E ÷ EPS growth rate | — | 58.08x | 6.84x | — | — |
| EV / EBITDAEnterprise value multiple | 16.20x | 13.28x | 10.87x | 126.43x | 8.53x |
| Price / SalesMarket cap ÷ Revenue | 0.91x | 1.49x | 0.61x | 0.97x | 1.80x |
| Price / BookPrice ÷ Book value/share | 2.12x | 1.32x | 1.79x | 3.63x | 2.30x |
| Price / FCFMarket cap ÷ FCF | 24.68x | 17.54x | 14.12x | — | 63.83x |
Profitability & Efficiency
AMSF leads this category, winning 8 of 9 comparable metrics.
Profitability & Efficiency
AMSF delivers a 9.7% return on equity — every $100 of shareholder capital generates $10 in annual profit, vs $-28 for DRVN. AMSF carries lower financial leverage with a 0.00x debt-to-equity ratio, signaling a more conservative balance sheet compared to DRVN's 6.58x. On the Piotroski fundamental quality scale (0–9), EYE scores 7/9 vs HSIC's 4/9, reflecting strong financial health.
| Metric | |||||
|---|---|---|---|---|---|
| ROE (TTM)Return on equity | +3.5% | +2.2% | +8.2% | -28.4% | +9.7% |
| ROA (TTM)Return on assets | +1.5% | +1.2% | +3.6% | -4.2% | +5.6% |
| ROICReturn on invested capital | +3.0% | +4.8% | +7.1% | -2.2% | +21.9% |
| ROCEReturn on capital employed | +3.8% | +4.9% | +9.8% | -2.7% | +16.8% |
| Piotroski ScoreFundamental quality 0–9 | 7 | 7 | 4 | 6 | 7 |
| Debt / EquityFinancial leverage | 0.80x | 0.55x | 0.77x | 6.58x | 0.00x |
| Net DebtTotal debt minus cash | $656M | $496M | $3.5B | $3.8B | -$61M |
| Cash & Equiv.Liquid assets | $39M | $1.2B | $156M | $170M | $62M |
| Total DebtShort + long-term debt | $695M | $1.7B | $3.7B | $4.0B | $491,000 |
| Interest CoverageEBIT ÷ Interest expense | 3.54x | 12.76x | 4.59x | -1.23x | — |
Total Returns (Dividends Reinvested)
EYE leads this category, winning 3 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in HSIC five years ago would be worth $8,746 today (with dividends reinvested), compared to $4,462 for EYE. Over the past 12 months, EYE leads with a +46.3% total return vs AMSF's -29.2%. The 3-year compound annual growth rate (CAGR) favors EYE at 0.7% vs DRVN's -21.2% — a key indicator of consistent wealth creation.
| Metric | |||||
|---|---|---|---|---|---|
| YTD ReturnYear-to-date | -12.0% | +12.0% | -8.2% | -5.2% | -18.3% |
| 1-Year ReturnPast 12 months | +46.3% | +44.2% | +5.9% | -24.6% | -29.2% |
| 3-Year ReturnCumulative with dividends | +2.2% | -30.3% | -11.7% | -51.1% | -24.8% |
| 5-Year ReturnCumulative with dividends | -55.4% | -46.6% | -12.5% | -51.1% | -18.9% |
| 10-Year ReturnCumulative with dividends | -18.0% | -13.1% | +5.3% | -48.5% | +31.8% |
| CAGR (3Y)Annualised 3-year return | +0.7% | -11.3% | -4.0% | -21.2% | -9.1% |
Risk & Volatility
Evenly matched — NVST and AMSF each lead in 1 of 2 comparable metrics.
Risk & Volatility
AMSF is the less volatile stock with a 0.23 beta — it tends to amplify market swings less than NVST's 1.65 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. NVST currently trades 79.8% from its 52-week high vs AMSF's 62.4% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | |||||
|---|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.62x | 1.65x | 0.73x | 0.68x | 0.23x |
| 52-Week HighHighest price in past year | $30.02 | $30.42 | $89.29 | $19.74 | $48.54 |
| 52-Week LowLowest price in past year | $14.38 | $16.33 | $61.95 | $9.80 | $29.42 |
| % of 52W HighCurrent price vs 52-week peak | +76.0% | +79.8% | +79.0% | +69.7% | +62.4% |
| RSI (14)Momentum oscillator 0–100 | 40.8 | 55.1 | 39.1 | 54.3 | 34.2 |
| Avg Volume (50D)Average daily shares traded | 1.4M | 2.4M | 1.2M | 2.0M | 212K |
Analyst Outlook
Evenly matched — EYE and DRVN each lead in 1 of 1 comparable metric.
Analyst Outlook
Analyst consensus: EYE as "Buy", NVST as "Hold", HSIC as "Hold", DRVN as "Buy", AMSF as "Buy". Consensus price targets imply 54.2% upside for EYE (target: $35) vs 11.2% for NVST (target: $27). AMSF is the only dividend payer here at 8.41% yield — a key consideration for income-focused portfolios.
| Metric | |||||
|---|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Hold | Hold | Buy | Buy |
| Price TargetConsensus 12-month target | $35.20 | $27.00 | $86.43 | $18.00 | $44.50 |
| # AnalystsCovering analysts | 14 | 19 | 32 | 15 | 6 |
| Dividend YieldAnnual dividend ÷ price | — | — | — | — | +8.4% |
| Dividend StreakConsecutive years of raises | 2 | — | 1 | 2 | 0 |
| Dividend / ShareAnnual DPS | — | — | — | — | $2.55 |
| Buyback YieldShare repurchases ÷ mkt cap | +0.2% | +4.1% | +10.5% | 0.0% | +2.1% |
HSIC leads in 1 of 6 categories (Valuation Metrics). AMSF leads in 1 (Profitability & Efficiency). 3 tied.
EYE vs NVST vs HSIC vs DRVN vs AMSF: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is EYE or NVST or HSIC or DRVN or AMSF a better buy right now?
For growth investors, National Vision Holdings, Inc.
(EYE) is the stronger pick with 9. 0% revenue growth year-over-year, versus 1. 5% for Driven Brands Holdings Inc. (DRVN). AMERISAFE, Inc. (AMSF) offers the better valuation at 12. 3x trailing P/E (14. 4x forward), making it the more compelling value choice. Analysts rate National Vision Holdings, Inc. (EYE) a "Buy" — based on 14 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — EYE or NVST or HSIC or DRVN or AMSF?
On trailing P/E, AMERISAFE, Inc.
(AMSF) is the cheapest at 12. 3x versus Envista Holdings Corp at 86. 7x. On forward P/E, Driven Brands Holdings Inc. is actually cheaper at 10. 9x — notably different from the trailing picture, reflecting expected earnings growth. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Henry Schein, Inc. wins at 4. 21x versus Envista Holdings Corp's 11. 53x.
03Which is the better long-term investment — EYE or NVST or HSIC or DRVN or AMSF?
Over the past 5 years, Henry Schein, Inc.
(HSIC) delivered a total return of -12. 5%, compared to -55. 4% for National Vision Holdings, Inc. (EYE). Over 10 years, the gap is even starker: AMSF returned +31. 8% versus DRVN's -48. 5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — EYE or NVST or HSIC or DRVN or AMSF?
By beta (market sensitivity over 5 years), AMERISAFE, Inc.
(AMSF) is the lower-risk stock at 0. 23β versus Envista Holdings Corp's 1. 65β — meaning NVST is approximately 612% more volatile than AMSF relative to the S&P 500. On balance sheet safety, AMERISAFE, Inc. (AMSF) carries a lower debt/equity ratio of 0% versus 7% for Driven Brands Holdings Inc. — giving it more financial flexibility in a downturn.
05Which is growing faster — EYE or NVST or HSIC or DRVN or AMSF?
By revenue growth (latest reported year), National Vision Holdings, Inc.
(EYE) is pulling ahead at 9. 0% versus 1. 5% for Driven Brands Holdings Inc. (DRVN). On earnings-per-share growth, the picture is similar: National Vision Holdings, Inc. grew EPS 202. 8% year-over-year, compared to -14. 5% for AMERISAFE, Inc.. Over a 3-year CAGR, DRVN leads at 16. 8% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — EYE or NVST or HSIC or DRVN or AMSF?
AMERISAFE, Inc.
(AMSF) is the more profitable company, earning 14. 9% net margin versus -12. 5% for Driven Brands Holdings Inc. — meaning it keeps 14. 9% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: AMSF leads at 18. 6% versus -6. 0% for DRVN. At the gross margin level — before operating expenses — NVST leads at 55. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is EYE or NVST or HSIC or DRVN or AMSF more undervalued right now?
The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.
By this metric, Henry Schein, Inc. (HSIC) is the more undervalued stock at a PEG of 4. 21x versus Envista Holdings Corp's 11. 53x. Both stocks trade at elevated growth-adjusted valuations, so expected growth needs to materialise. On forward earnings alone, Driven Brands Holdings Inc. (DRVN) trades at 10. 9x forward P/E versus 32. 6x for National Vision Holdings, Inc. — 21. 7x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for EYE: 54. 2% to $35. 20.
08Which pays a better dividend — EYE or NVST or HSIC or DRVN or AMSF?
In this comparison, AMSF (8.
4% yield) pays a dividend. EYE, NVST, HSIC, DRVN do not pay a meaningful dividend and should not be held primarily for income.
09Is EYE or NVST or HSIC or DRVN or AMSF better for a retirement portfolio?
For long-horizon retirement investors, AMERISAFE, Inc.
(AMSF) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 23), 8. 4% yield). Envista Holdings Corp (NVST) carries a higher beta of 1. 65 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (AMSF: +31. 8%, NVST: -13. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between EYE and NVST and HSIC and DRVN and AMSF?
These companies operate in different sectors (EYE (Consumer Cyclical) and NVST (Healthcare) and HSIC (Healthcare) and DRVN (Consumer Cyclical) and AMSF (Financial Services)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.
In terms of investment character: EYE is a small-cap quality compounder stock; NVST is a small-cap quality compounder stock; HSIC is a small-cap quality compounder stock; DRVN is a small-cap quality compounder stock; AMSF is a small-cap deep-value stock. AMSF pays a dividend while EYE, NVST, HSIC, DRVN do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.